Rodman & Renshaw Initiates Coverage on MediciNova (MNOV) with an Outperform
More News related to MNOV
- Data From MediciNova's Two-Year Phase II Clinical Trial of MN-166 in Multiple Sclerosis Presented At the World Congress for Treatment and Research in MS (WCTRIMS)
- MediciNova (MNOV) Reports Positive Preliminary Results from Phase II Clinical Trial of MN-221
- MediciNova Reports Positive Preliminary Results from Phase II Clinical Trial of MN-221 in Moderate to Severe Asthma Patients
- MediciNova to Present At Merriman Curhan Ford's 5th Annual Investor Summit 2008
- MediciNova Reports Second Quarter 2008 Results
More News related to New Coverage
- Morgan Stanley Starts Interpublic Group (IPG) at Underweight
- Morgan Stanley Starts Omnicom Grou (OMC) at Underweight
- JP Morgan Starts Harley-Davidson (HOG) at Neutral
- Keefe, Bruyette and Woods Initiates Coverage on Lakeland Bancorp (LBAI) with a Market Perform
- Morgan Stanley Upgrades Nokia (NOK) and Alcatel-Lucent (ALU) to Overweight
Rodman & Renshaw initiates coverage on MediciNova (Nasdaq: MNOV) with an Outperform. Price target $9.
MediciNova, Inc. is a biopharmaceutical company focused on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the United States market.
Related Categories
New CoverageStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
